Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile…
Preliminary Research on Late Life Depression and Accelerated Depression Treatment Protocol will be FeaturedBURLINGTON, Mass. and JERUSALEM, Sept. 27, 2023…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral…
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed…
Brain Canada’s Future Leaders in Canadian Brain Research program to support 28 early-career researchers this year The 2022 Future Leaders…
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British…
Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical researchDURHAM, N.C., Sept. 20, 2023…
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,…
Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and…
Purchases All 5,323,451 Shares Validly Tendered at $0.70 per SharePALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) --…